Organic Sythesis

有机合成核心设施(OSCF)的任务是向 MSKCC社区，并保持最先进的设施，拥有专业的化学专业人员 综合。这个化学核心设施运行在化学、生物和医学的界面上，并具有 支持医学化学工作的能力，以进化出阴性试剂，以支持MSKCC调查人员。 该中心的工作极大地促进了该中心的临床前研究。《核心》综合小说 不容易获得的分子，通过遵循所述的程序或通过开发新的和 更适合的合成方法。MSKCC致力于新工具的研发 以及用于癌症检测、预防和治疗的治疗剂。由提供的专业化服务 在过去的一年里，有机合成核心支持了16名研究人员的研究。在过去 授权期核心的工作为来自5项研究的60篇研究人员的出版物做出了贡献 程序。例如，Sawyers实验室利用Core的服务开发了一种新的雄激素 受体拮抗剂作为前列腺癌的潜在治疗药物。在相对较短的时间内，核心能够 发明一种新的化学方法来合成一种安全、可扩展和可重现的拮抗剂。多数 重要的是，对交付批次的控制使得在批次生物利用度时调整方法变得很容易 评估结果差异很大。到目前为止，这已经产生了两项许可专利，一份备受瞩目的论文，以及 最重要的是，一种具有理想性能的药物，现在被称为ARN-509，不久将进入第三阶段 对去势耐药前列腺癌的评价。

The mission of the Organic Synthesis Core Facility (OSCF) is to provide chemical synthesis services to the MSKCC community, and to maintain a state-of-the art facility with expert professional personnel in chemical synthesis. This Chemistry Core Facility operates at the interface of chemistry, biology and medicine, and has the capability to support medical chemistry efforts to evolve neg agents in support of MSKCC investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures or by developing new and more suitable methods of synthesis. MSKCC is committed to the research and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The specialized services provided by the Organic Synthesis Core have supported the research of 16 investigators in the past year. During the past grant period the work of the Core has contributed to 60 publications of researchers from 5 research programs. For example, the Sawyers laboratory used the Core's services to develop a new androgen receptor antagonist as a potential therapy for prostate cancer. In a relatively short time, the Core was able to invent a new chemical process to synthesize an antagonist that was safe, scalable, and reproducible. Most importantly, controls of delivered batches made it easy to adjust the methodology when batch bioavailability assessments varied significantly. This has so far resulted in two licensed patents, a high profile paper, and most importantly a drug with desirable properties, now known as ARN-509, that will shortly enter Phase III evaluation in castrate resistant prostate cancer.